| Hypertensive disease
Benicar vs Norliqva
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Benicar vs Norliqva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNorliqva has a higher rate of injection site reactions vs Benicar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Norliqva but not Benicar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benicar
Norliqva
At A Glance
Oral
Daily
Angiotensin II receptor antagonist
Oral
Daily
Calcium channel blocker
Indications
- Hypertensive disease
- Hypertensive disease
- Stable angina
- Coronary heart disease
Dosing
Hypertensive disease (Adults) Starting dose 20 mg once daily; may increase to 40 mg once daily after 2 weeks if further blood pressure reduction needed; oral.
Hypertensive disease (Pediatric, 6 years and older) 10 mg once daily for patients weighing 20 to <35 kg; 20 mg once daily for patients weighing >=35 kg; oral tablet or extemporaneous suspension.
Hypertensive disease Adults: 5 mg orally once daily (max 10 mg); small, fragile, elderly, or hepatic insufficiency patients start at 2.5 mg once daily; pediatric patients (>=6 years): 2.5-5 mg orally once daily.
Stable angina 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary heart disease 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- Known sensitivity to amlodipine
Adverse Reactions
Most common (>1%) Dizziness
Postmarketing Asthenia, angioedema, anaphylactic reactions, vomiting, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, increased blood creatinine levels, alopecia, pruritus, urticaria
Most common (>1%) Edema, dizziness, flushing, palpitation, fatigue, nausea.
Postmarketing Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder.
Pharmacology
Olmesartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist that blocks vasoconstrictor effects of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle, acting independently of angiotensin II synthesis pathways.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, acting as a peripheral arterial vasodilator to reduce peripheral vascular resistance and blood pressure, and relieving angina by reducing myocardial oxygen demand and blocking coronary vasospasm.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benicar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (1/12)
Norliqva
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (6/12)
UnitedHealthcare
Benicar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Norliqva
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Benicar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Norliqva
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Benicar.
No savings programs available for Norliqva.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenicarView full Benicar profile
NorliqvaView full Norliqva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.